Challenges of quitting smoking and lung cancer screening
Editorial

Challenges of quitting smoking and lung cancer screening

Giulia Carreras, Giuseppe Gorini

Cancer Prevention and Research Institute (ISPO), Florence, Italy

Correspondence to: Giulia Carreras. Cancer Prevention and Research Institute (ISPO), via delle Oblate 2, Florence 50134, Italy. Email: g.carreras@ispo.toscana.it.

Provenance: This is an invited Editorial commissioned by Section Editor Jianrong Zhang, MD (George Warren Brown School of Social Work, Washington University in St. Louis, St. Louis, USA).

Comment on: Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax 2017;72:912-8.


Submitted Sep 12, 2017. Accepted for publication Sep 25, 2017.

doi: 10.21037/atm.2017.09.40


Evidence on the effect of lung cancer screening on smoking cessation

In a recent publication, Brain and colleagues showed that participants to the UK Lung Cancer Screening (UKLS) pilot trial significantly increased smoking cessation in two years compared to non-participants. In fact, 15% of smokers in the screening arm and 10% in the control arm successfully quitted at two years from the first screening. The effect of the trial arm on quitting smoking was significant, with cessation rates of 15% and 10% at 2 years in intervention and control arms, respectively (1).

This result is in line with those of other randomized trials on screening for lung cancer with low-dose computed tomography (LDCT) that investigated the impact on smoking cessation.

The Danish Lung Cancer Screening Trial (DLCST) found a quit rate of 12% and a relapse rate of 11% in both arms at 1 year. The annual point prevalence quit rate increased to 24% after five screening rounds, whereas the relapse rate remained stable (2).

The NELSON trial on Dutch-Belgian males found a smoking abstinence at 2 years follow-up of about 14% in both arms (3).

In the US National Lung Screening Trial (NLST), which is the only study in which the control arm does chest radiography instead of usual care, after one year from the third screen 24% of smokers in both arms quitted, and higher quit rates were recorded in smokers with any screen-detected abnormality compared with those with normal screening results (4).

The effect of LDCT screening on smoking cessation was investigated also in three cohort studies carried out in US, namely the Early Lung Cancer Action Project (ELCAP), the Mayo study, and Pittsburgh Lung Screening Study (PLuSS) (5-8). The ELCAP study found a 35% cessation rate at 1 year and a prolonged abstinence of 29% (6). In the Mayo study the proportion of quitters after 1 and 3 years was 14% and 12%; moreover, 10% of former smokers relapsed after 1 and 3 years (7). The PLuSS study reported a quit rate of 16% after 1 year (8).

In all these studies, cohorts and trials, participants in both control and screening arms were offered a minimal smoking cessation intervention (smoking cessation brochure, information on smoking cessation centres, short counseling), and cessation rates were higher than those observed in the general population: 4% in the UK and Danish population (1,2), 3–7% in the Dutch population (3).

Moreover, in some studies (NLST, ELCAP, MAYO, PLuSS) a sort of dose-response relationship among the type or number of abnormalities in screen results and cessation was observed (4,5).

All these findings deny the hypothesis that undergoing LDCT screening may result in justification of continuing smoking and support instead the hypothesis that enrolment in screening may increase quitting (9).


Promoting smoking cessation in lung cancer screening programmes

Carrying out a LDCT test, as well as being involved in the control arm of a LDCT screening trial, increase quitting. However, in some trials (UKLS) cessation rates were significantly higher in experimental arm, whereas in others (DLCST, NELSON, NLST) no differences were observed by study arm. In the control arm of NLST a chest radiography examination was provided, and this could have determined similar cessation rates in both arms. On the contrary, in the UKLS trial, controls received usual care only, and this could explain their lower cessation rates. No conclusive results are available on the impact of LDCT test on smoking cessation rates in comparison to controls.

At least a part of the observed decline in smoking rates in both arms could be due to an overall effect of participation in trials, and to the voluntary nature of participating smokers who already have been contemplating quitting (1). There is evidence that heavy smokers, maybe less motivated to quit, are less likely to attend screening tests due to their pessimistic attitudes and fatalistic beliefs (10,11).

Therefore, screening could be an occasion to select smokers contemplating or ready to quit, that usually record higher cessation rates (12). Then, tailored smoking cessation programmes, that include both individual or group counseling and pharmacologic treatments, should be incorporated in the screening.


The impact of smoking cessation on mortality in lung cancer screening trials

There are few studies that estimated the impact of screening by smoking habits. In NLST current smokers at recruitment had a two-fold risk of dying from lung cancer compared to former smokers (13). Part of the reduction in mortality in current smokers could be due to quitting smoking in the study period. In fact, in the Italian cohorts selected from the Multicentric Italian Lung Detection (MILD) trial and its pilot, late quitters (those who stopped during follow-up) reported a 35% reduction in mortality, whereas early quitters (those who stopped before baseline) reported a 43% reduction in mortality compared to continuing smokers (14).

Those who stopped smoking have a reduced risk of dying from lung cancer and from other causes, and, above all, from cardiovascular diseases, compared to smokers. Results from the MILD cohorts showed that the effect of stopping smoking in participants undergoing repeated LDCT screening was to significantly reduce the overall mortality: stopping smoking showed a positive effect on overall mortality three-fold to five-fold greater than that achieved by early detection in the NLST (14).

Moreover, stopping smoking is more effective than screening even on lung cancer mortality. In fact, whereas the relative risk of death from lung cancer for current smokers compared to former smokers is around 3 (15), the relative risk of death from lung cancer in NLST control arm compared to screening arm is about 1.25 (16).


Cost-effectiveness of lung cancer screening programmes

Although the sensitivity of LDCT screening is quite high, e.g., over 90% across the three screening rounds in NLST, the specificity is still low, ranging from 73% to 84% (16). This determines a large number of false positives, which often require additional follow-up examinations, enhancing costs.

Screening was proved to prevent the greatest number of deaths from lung cancer among NLST participants who were at highest risk (17), therefore a strictly targeted programme could be more effective (18). This was done in the UKLS pilot trial where participants were selected using a prediction model which includes age, sex, family history of lung cancer, smoking duration, personal history of other cancers and non-malignant respiratory diseases, and asbestos exposure (1). In most trials, the selection of participants was only based on age (e.g., between 55 and 74 years) and smoking history (e.g., a minimum of 30 pack-years of smoking and no more than 15 years since quitting).

In terms of cost-effectiveness, the NLST LDCT screening was reported to be cost-effective by US standards, yielding estimated incremental cost-effectiveness ratios (ICERs) of US$52,000 per life-year gained and US$81,000 per quality-adjusted life-year (QALY) gained (19). If stringent eligibility criteria are applied, LDCT screening could be cost-effective also at a population level: annual screening between ages 60–75 for persons who smoked ≥40 pack-years and who currently smoke or quit ≤10 years ago (about 10% of the US population) yielded an ICER of US$41,114 per life-year gained (20). By further selecting the highest-risk screened sample, an ICER of CAD$20,724/QALY was found (21).


Combination of smoking cessation interventions and lung cancer screening

Interventions for smoking cessation are more cost-effective than LDCT screening, given the lower costs and the higher effectiveness in preventing overall mortality. As an example, an annual smoking cessation therapy (e.g., repeated each year if continuing smoking) that costs about US$300 and achieves a 16% 1-year abstinence rate, recorded an ICER of about US$15,800/QALY (22).

However, delivering smoking cessation interventions only would not allow to prevent lung cancer deaths in hardcore and former smokers.

Combining lung cancer screening with an intensified smoking cessation programme would yield a 9% reduction in cumulative lung cancer mortality 25 years after their introduction in a US region with a relatively high smoking prevalence and lung cancer incidence (23). In Italy, combining a smoking cessation intervention (funding treatment, setting up an active quitline, promoting counseling among health professionals, enhancing cigarettes’ taxes) with a three-round annual LDCT screen for current and former heavy smokers aged 55 to 74 years, could reduce overall and lung cancer mortality by respectively 33% and 26% compared to no intervention after 25 years. Screening could bring an early decrease in lung cancer and respiratory diseases, followed by a more substantial drop in all-cause deaths in subsequent decades due to tobacco control policies (24).

The integration of cessation interventions could enhance the cost-effectiveness of LDCT screening. Annual combined screening ad cessation therapy programmes recorded an ICER around US$152,000/QALY (22). An organized screening programme with a cessation intervention have an ICER of CAD$33,420 and CAD$29,820 for 15% and 25% levels of smoking cessation (25).


Conclusions

Given that participation to screening increases smoking cessation, which could be further increased by integrating smoking cessation programmes into the screening pathway, combining smoking cessation intervention with LDLC screening could be the best strategy. Further studies are needed in order to find the best options to integrate both interventions.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax 2017;72:912-8. [Crossref] [PubMed]
  2. Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme. Thorax 2014;69:574-9. [Crossref] [PubMed]
  3. van der Aalst CM, van den Bergh KA, Willemsen MC, et al. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010;65:600-5. [Crossref] [PubMed]
  4. Tammemägi MC, Berg CD, Riley TL, et al. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst 2014;106:dju084. [Crossref] [PubMed]
  5. Slatore CG, Baumann C, Pappas M, et al. Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. preventive services task force. Ann Am Thorac Soc 2014;11:619-27. [Crossref] [PubMed]
  6. Anderson CM, Yip R, Henschke CI, et al. Smoking cessation and relapse during a lung cancer screening program. Cancer Epidemiol Biomarkers Prev 2009;18:3476-83. [Crossref] [PubMed]
  7. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer 2005;103:2154-62. [Crossref] [PubMed]
  8. Styn MA, Land SR, Perkins KA, et al. Smoking behavior 1 year after computed tomography screening for lung cancer: Effect of physician referral for abnormal ct findings. Cancer Epidemiol Biomarkers Prev 2009;18:3484-9. [Crossref] [PubMed]
  9. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29. [Crossref] [PubMed]
  10. Carreras G, Iannucci L, Costa G, et al. Are smokers less likely to seek preventive healthcare measures in Italy? Eur J Cancer Prev 2017. [Epub ahead of print]. [Crossref] [PubMed]
  11. Quaife SL, McEwen A, Janes SM, et al. Smoking is associated with pessimistic and avoidant beliefs about cancer: results from the International Cancer Benchmarking Partnership. Br J Cancer 2015;112:1799-804. [Crossref] [PubMed]
  12. Gorini G, Carreras G, Giordano L, et al. The Pap smear screening as an occasion for smoking cessation and physical activity counselling: effectiveness of the SPRINT randomized controlled trial. BMC Public Health 2012;12:740. [Crossref] [PubMed]
  13. Tanner NT, Kanodra NM, Gebregziabher M, et al. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 2016;193:534-41. [Crossref] [PubMed]
  14. Pastorino U, Boffi R, Marchianò A, et al. Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants. J Thorac Oncol 2016;11:693-9. [Crossref] [PubMed]
  15. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012;131:1210-9. [Crossref] [PubMed]
  16. Aberle DR, Adams AM, Berg CD, et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011;365:395-409. [Crossref] [PubMed]
  17. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54. [Crossref] [PubMed]
  18. Ten Haaf K, Jeon J, Tammemägi MC, et al. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Med 2017;14:e1002277. [Crossref] [PubMed]
  19. Black WC, Gareen IF, Soneji SS, et al. Cost-Effectiveness of CT Screening in the National Lung Screening Trial. N Engl J Med 2014;371:1793-802. [Crossref] [PubMed]
  20. Ten Haaf K, Tammemägi MC, Bondy SJ, et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med 2017;14:e1002225. [Crossref] [PubMed]
  21. Cressman S, Peacock SJ, Tammemägi MC, et al. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. J Thorac Oncol 2017;12:1210-22. [Crossref] [PubMed]
  22. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011;6:1841-8. [Crossref] [PubMed]
  23. Tramontano AC, Sheehan DF, McMahon PM, et al. Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. BMJ Open 2016;6:e010227. [Crossref] [PubMed]
  24. Carreras G, Gorini G, Paci E. Can a national lung cancer screening program in combination with smoking cessation policies cause an early decrease in tobacco deaths in Italy? Cancer Prev Res (Phila) 2012;5:874-82. [Crossref] [PubMed]
  25. Goffin JR, Flanagan WM, Miller AB, et al. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness. Lung Cancer 2016;101:98-103. [Crossref] [PubMed]
Cite this article as: Carreras G, Gorini G. Challenges of quitting smoking and lung cancer screening. Ann Transl Med 2017;5(24):488. doi: 10.21037/atm.2017.09.40

Refbacks

  • There are currently no refbacks.